Experts are calling for clearer operational guidance as homologous recombination deficiency (HRD) testing becomes a standard in ovarian cancer treatment. This episode distills expert views on choosing the right tests, understanding their results, and implementing them within established care guidelines.
Key takeaways include the fundamental principles of HRD testing, nuanced aspects of test selection and reporting impacting patient management, workflow integration across oncology, pathology, and genetics, and applying test outcomes to maintenance strategies and patient discussions.
Leading oncologists from UAB O’Neal Comprehensive Cancer Center, West Penn Hospital, and NYU Langone Health shared their insights.